European Heart Journal Advance Access published online on April 24, 2007
European Heart Journal, doi:10.1093/eurheartj/ehm019
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes
1 The Duke Clinical Research Institute, Durham, NC, USA
2 McMaster University, Hamilton, Ontario, Canada
3 The Duke Translational Medicine Institute, Durham, NC, USA
4 University Hospital Minjoz, Besancon, France
Received 20 September 2006; revised 18 January 2007; accepted 15 February 2007.
* Corresponding author. Durham VA Medical Center, 508 Fulton Street (111A), Durham, NC 27705, USA. Tel: +1 919 286 0411, ext 2352; fax: +1 919 286 6821. E-mail address: sunil.rao{at}duke.edu
Antithrombotic therapy and invasive risk stratification in selected high-risk patients have improved outcomes from non-ST-segment elevation acute coronary syndromes (NSTE-ACS), but carry a risk of bleeding and blood transfusion. Although the true incidence of bleeding depends on the population studied (i.e. clinical trial vs. registry), the definition used, and the use of invasive procedures, it is becoming clear that bleeding is associated with an increased risk for adverse outcomes including myocardial infarction and death. Blood transfusion itself may carry a risk for ischaemic outcomes that is independent of bleeding. Therefore, therapies that provide an adequate level of anticoagulation to reduce ischaemia while simultaneously minimizing the risk of bleeding and transfusion have the potential to improve outcomes among patients with NSTE-ACS. Anticoagulants studied in recent clinical trials that have focused on bleeding reduction include fondaparinux and bivalirudin. In this review, we discuss the clinical trial evidence for these agents, the association between bleeding and clinical outcomes, the biology of blood transfusion and potential mechanisms underlying its association with adverse outcomes, and propose strategies to deal with bleeding complications. Future directions for research and clinical practice are also discussed.
Key Words: Acute coronary syndromes • Haemorrhage • Blood transfusion
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. M. Jolic{oelig}ur, W. W. O'Neill, A. Hellkamp, C. W. Hamm, D. R. Holmes Jr., H. R. Al-Khalidi, M. R. Patel, F. J. Van de Werf, K. Pieper, P. W. Armstrong, et al. Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention Eur. Heart J., November 1, 2009; 30(21): 2575 - 2583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Serebruany, S. V. Rao, M. A. Silva, J. L. Donovan, A. O. Kannan, L. Makarov, S. Goto, and D. Atar Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications Eur. Heart J., October 23, 2009; (2009) ehp434v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. van Hattum, A. Algra, J. A. Lawson, B. C. Eikelboom, F. L. Moll, and M. J.D. Tangelder Bleeding Increases the Risk of Ischemic Events in Patients With Peripheral Arterial Disease Circulation, October 20, 2009; 120(16): 1569 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mehran, S. J. Pocock, G. W. Stone, T. C. Clayton, G. D. Dangas, F. Feit, S. V. Manoukian, E. Nikolsky, A. J. Lansky, A. Kirtane, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial Eur. Heart J., June 2, 2009; 30(12): 1457 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Mehta, A. D. Frutkin, J. B. Lindsey, J. A. House, J. A. Spertus, S. V. Rao, F.-S. Ou, M. T. Roe, E. D. Peterson, S. P. Marso, et al. Bleeding in Patients Undergoing Percutaneous Coronary Intervention: The Development of a Clinical Risk Algorithm From the National Cardiovascular Data Registry Circ Cardiovasc Interv, June 1, 2009; 2(3): 222 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Hamm Bleeding management and pharmacological strategy in primary percutaneous coronary intervention Eur. Heart J. Suppl., June 1, 2009; 11(suppl_C): C9 - C12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Subherwal, R. G. Bach, A. Y. Chen, B. F. Gage, S. V. Rao, L. K. Newby, T. Y. Wang, W. B. Gibler, E. M. Ohman, M. T. Roe, et al. Baseline Risk of Major Bleeding in Non-ST-Segment-Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score Circulation, April 14, 2009; 119(14): 1873 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Angiolillo Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions Diabetes Care, April 1, 2009; 32(4): 531 - 540. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Z. Potsis, C. Katsouras, and J. A. Goudevenos Avoiding and Managing Bleeding Complications in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Angiology, April 1, 2009; 60(2): 148 - 158. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Doyle There Will Be Blood J. Am. Coll. Cardiol. Intv., January 1, 2009; 2(1): 54 - 55. [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Hamm, H. Möllmann, J.-P. Bassand, and F. van de Werf CHAPTER 16 Acute Coronary Syndromes ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. De Luca Adjunctive antithrombotic therapy during primary percutaneous coronary intervention Eur. Heart J. Suppl., December 1, 2008; 10(suppl_J): J2 - J14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Mehta, W. E. Boden, J. W. Eikelboom, M. Flather, P. G. Steg, A. Avezum, R. Afzal, L. S. Piegas, D. P. Faxon, P. Widimsky, et al. Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes: An Individual Patient-Level Combined Analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials Circulation, November 11, 2008; 118(20): 2038 - 2046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Rao and S. Y.H. Kim Informing the Consent Process Circ Cardiovasc Qual Outcomes, September 1, 2008; 1(1): 7 - 8. [Full Text] [PDF]
|
|
|
|
 |
|
 A J Chase, E B Fretz, W P Warburton, W P Klinke, R G Carere, D Pi, B Berry, and J D Hilton Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg) Heart, August 1, 2008; 94(8): 1019 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Bassand Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm Heart, May 1, 2008; 94(5): 661 - 666. [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|